135 related articles for article (PubMed ID: 27036915)
21. Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion.
Ghosh A; Wolenski M; Klein C; Welte K; Blazar BR; Sauer MG
J Immunother; 2008; 31(2):121-31. PubMed ID: 18481382
[TBL] [Abstract][Full Text] [Related]
22. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
23. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
Zeh HJ; Perry-Lalley D; Dudley ME; Rosenberg SA; Yang JC
J Immunol; 1999 Jan; 162(2):989-94. PubMed ID: 9916724
[TBL] [Abstract][Full Text] [Related]
24. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
[TBL] [Abstract][Full Text] [Related]
25. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
26. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL.
Derby M; Alexander-Miller M; Tse R; Berzofsky J
J Immunol; 2001 Feb; 166(3):1690-7. PubMed ID: 11160212
[TBL] [Abstract][Full Text] [Related]
27. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.
Koido S; Tanaka Y; Tajiri H; Gong J
Vaccine; 2007 Mar; 25(14):2610-9. PubMed ID: 17239504
[TBL] [Abstract][Full Text] [Related]
28. Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: in vitro and in vivo studies.
Leshem B; Dorfman Y; Kedar E
Cancer Immunol Immunother; 1999 Jul; 48(4):179-88. PubMed ID: 10431687
[TBL] [Abstract][Full Text] [Related]
29. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
[TBL] [Abstract][Full Text] [Related]
31. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2RĪ³null mouse model.
Masaki A; Ishida T; Suzuki S; Ito A; Mori F; Sato F; Narita T; Yamada T; Ri M; Kusumoto S; Komatsu H; Tanaka Y; Niimi A; Inagaki H; Iida S; Ueda R
J Immunol; 2013 Jul; 191(1):135-44. PubMed ID: 23733874
[TBL] [Abstract][Full Text] [Related]
32. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
33. Clonal analysis of cytolytic T lymphocyte-mediated lysis of target cells with inducible antigen expression: correlation between antigen density and requirement for Lyt-2/3 function.
Shimonkevitz R; Luescher B; Cerottini JC; MacDonald HR
J Immunol; 1985 Aug; 135(2):892-9. PubMed ID: 2409156
[TBL] [Abstract][Full Text] [Related]
34. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
35. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
[TBL] [Abstract][Full Text] [Related]
36. [In Vivo Antigen Delivery to Dendritic Cells-A Novel Peptide Vaccine for Cancer Therapy].
Mizumoto Y; Katsuda M; Miyazawa M; Kitahata Y; Miyamoto A; Nakamori M; Ojima T; Matsuda K; Hemmi H; Tamada K; Kaisho T; Yamaue H
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1469-1471. PubMed ID: 30382048
[TBL] [Abstract][Full Text] [Related]
37. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
39. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
40. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
